Significantly elevated liver enzymes (ALT 180 U/L, AST 165 U/L) indicate acute hepatic dysfunction and potential liver damage, which poses immediate risks to maternal and fetal health in pregnancy with hepatitis B.
The most concerning assessment finding for a pregnant client at 32 weeks gestation with a known hepatitis B infection is elevated liver enzymes (ALT 180 U/L, AST 165 U/L). While a positive HBsAg confirms the chronic carrier state and symptoms like fatigue or dark urine are expected manifestations of hepatitis, a significant transaminase elevation signals active hepatocellular injury. In the context of pregnancy, this finding demands immediate attention not only due to the viral infection itself but because it can be a sentinel sign of superimposed, pregnancy-specific hepatic complications that carry a high risk of maternal and fetal morbidity [4].
The physiological changes of pregnancy alter the baseline interpretation of liver function. For instance, alkaline phosphatase rises physiologically due to placental production, while albumin and bilirubin levels typically decrease [4]. However, transaminases such as ALT and AST do not undergo significant pregnancy-induced changes. Therefore, a marked elevation to the levels presented here is a definitive indicator of pathology rather than a normal gestational adaptation [4]. The nurse must recognize that this degree of hepatocellular damage can rapidly progress. A systematic review on drug-induced liver injury in pregnancy highlights how initially mild symptoms can quickly evolve into fulminant hepatic failure within days, requiring prompt intervention to prevent a fatal outcome [1]. Although that review focused on a pharmacological trigger, the clinical trajectory of rapid decompensation from acute hepatocellular injury is a critical concept applicable to any severe hepatic insult during pregnancy.
Furthermore, the differential diagnosis in a pregnant patient with jaundice and elevated transaminases must include conditions unique to gestation, such as intrahepatic cholestasis of pregnancy (ICP). While ICP is classically associated with pruritus and elevated bile acids, emerging research demonstrates that dysregulated metabolic pathways, including iron metabolism, play a role in its pathophysiology [2]. This underscores that hepatic disorders in pregnancy are complex and multifactorial. The presence of dark urine and clay-colored stools, while indicative of cholestasis, is a less specific and less immediately ominous finding than a direct marker of ongoing liver cell necrosis. The nurse’s priority is to identify the finding that signals the highest risk for acute clinical deterioration, which is the objective evidence of severe hepatocellular injury reflected in the elevated ALT and AST levels [1][4].
References (research sources)
[1]
Hepatotoxicity Associated with Labetalol Use: A Case Report with Systematic Review and Disproportionality Analysis Using FAERS.Meta-analysis/systematic reviewHendriksen ED, Rieder M, Urbantke E. (2026) · DOI: 10.1002/jcph.70192
[2]
Analyzing the association between ferritin levels and ICP using machine learning algorithms: a retrospective case-control study.Research articleWei N, Guo S, Liu X, Zhang J, Liu J, Chen Q, Dai W. (2026) · DOI: 10.3389/fmed.2026.1804534
[4]
Liver function disorders in pregnancy: physiology or pathology?Research articleSielwanowska-Lasek W, Mądro A. (2026) · DOI: 10.5114/pg.2026.160319
Clinical Practice Guide: Managing Hepatitis B with Elevated Transaminases in Pregnancy
1. Immediate Nursing Actions
Prioritize Assessment: Immediately perform a complete set of vital signs, assess for right upper quadrant (RUQ) pain, nausea/vomiting, and changes in mental status. Evaluate deep tendon reflexes and check for dependent edema.
Differentiate the Etiology: A critical nursing responsibility is to help distinguish between an acute exacerbation of hepatitis B and a pregnancy-specific hypertensive disorder like severe preeclampsia or HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets). Assess for hypertension and proteinuria.
Notify the Provider: Report the elevated transaminases (ALT 180 U/L, AST 165 U/L) and the complete clinical picture immediately. Use SBAR communication, emphasizing the potential for rapid deterioration.
2. Ongoing Monitoring and Surveillance
Laboratory Trends: Anticipate serial monitoring of a complete liver panel (ALT, AST, bilirubin, alkaline phosphatase), a coagulation profile (PT/INR, aPTT, fibrinogen), and a complete blood count with platelet count to screen for HELLP syndrome and hepatic synthetic dysfunction.
Fetal Surveillance: Initiate continuous electronic fetal monitoring to assess for signs of fetal compromise related to maternal illness. A non-stress test or biophysical profile may be ordered.
Maternal Status: Frequently reassess for signs of advancing liver failure, including jaundice, hypoglycemia, and encephalopathy (confusion, asterixis). Monitor intake and output strictly.
3. Safety and Collaborative Interventions
Prevent Bleeding: With impaired liver function, coagulation factors may be depleted. Institute bleeding precautions: avoid intramuscular injections, use smallest gauge needle for IVs, apply prolonged pressure after venipuncture, and avoid rectal procedures or medications.
Medication Review: Collaborate with the pharmacy and provider to review all medications, including over-the-counter drugs, for hepatotoxic potential. Acetaminophen use must be strictly limited and ordered by the provider.
Prepare for Escalation: Have emergency equipment ready. Prepare for a potential rapid transfer to a labor and delivery unit with a higher level of care or an intensive care unit. Anticipate urgent consultations with maternal-fetal medicine, hepatology, and possibly transplant services.
4. Psychosocial and Postpartum Planning
Address Anxiety: The client and family will be acutely aware of the seriousness of the situation. Provide clear, calm explanations of the monitoring and interventions being performed.
Vertical Transmission Prevention: Reiterate the plan for the newborn to receive both hepatitis B immune globulin (HBIG) and the first dose of the hepatitis B vaccine within 12 hours of birth, which is the standard of care to prevent perinatal transmission.
Hepatitis B — Hepatitis B. An inflammatory disease of the liver caused by the hepatitis B virus (HBV).
ALT (Alanine Aminotransferase) / AST (Aspartate Aminotransferase) — Alanine aminotransferase / aspartate aminotransferase. Enzymes present within liver cells; a key indicator that, when blood levels are elevated, signifies liver cell damage or necrosis.
Vertical Transmission — Vertical transmission. The transmission of disease from mother to fetus or newborn. One of the main transmission routes of hepatitis B, occurring through contact during childbirth.
HBsAg (Hepatitis B Surface Antigen) — Hepatitis B surface antigen. A marker that, when detected in serum, indicates current infection with the hepatitis B virus. Used for diagnosis.
HBIG (Hepatitis B Immune Globulin) — Hepatitis B immune globulin. A serum preparation containing antibodies against the hepatitis B virus. Used to prevent vertical transmission by administering to newborns born to HBsAg-positive mothers within 12 hours after birth.